Evidence map›Paper›PMID 42707259›Full record

ArticleFrontiers in immunology2026

A viral-vectored multipathogen vaccine platform based on replication-competent vaccinia virus and adeno-associated virus.

Yuna Sato, Yutaro Yamamoto, Ammar Abdurrahman Hasyim, Takeshi Morita, Koichi Watashi, Akihiko Sakamoto, Takuto Katayama, Kartika Hardianti Zainal, Mitsuhiro Iyori, Hiroaki Mizukami and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuna SatoLaboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Ishikawa, Japan.
Yutaro YamamotoLaboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Ishikawa, Japan.
Ammar Abdurrahman HasyimLaboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Ishikawa, Japan.
Takeshi MoritaDepartment of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Koichi WatashiDepartment of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
Akihiko SakamotoLaboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Ishikawa, Japan.
Takuto KatayamaLaboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Ishikawa, Japan.
Kartika Hardianti ZainalLaboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Ishikawa, Japan.
Mitsuhiro IyoriResearch Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
Hiroaki MizukamiDivision of Gene Therapy, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Hisatoshi ShidaLaboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Kyoto University, Kyoto, Japan.
Shigeto YoshidaLaboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa, Ishikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multi pathogen vaccines have emerged as a promising strategy to improve vaccine coverage, simplify immunization logistics, and address overlapping global health threats. However, few vaccine platforms have demonstrated robust and durable immune responses against pathogens spanning distinct biological classes. Here, we developed and evaluated a viral-vectored multipathogen vaccine platform based on a heterologous prime-boost regimen combining the highly attenuated vaccinia virus LC16m8Δ (m8Δ) and adeno-associated virus serotype 1 (AAV1). As a preclinical proof-of-concept, antigen-specific immune responses against

Indexed as

COVID-19COVID-19 VaccinesDependovirusGenetic VectorsMalaria, FalciparumMalaria VaccinesSARS-CoV-2Vaccinia virusAnimalsAntibodies, NeutralizingFemaleHumansMiceMice, Inbred BALB CPlasmodium bergheiPlasmodium falciparumAntibodies, NeutralizingCOVID-19 VaccinesMalaria Vaccinesadeno-associated virusLC16m8Δmultipathogen vaccineprime-boost immunizationvaccine platformviral vector

Identifiers

PMID42707259
PMCPMC13547518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.